Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Studies show benefit of predialysis erythropoietin administration

Nov. 30, 2006

Liraglutide added to metformin improves glucose levels in type 2 diabetes

Nov. 30, 2006

Promising preliminary clinical results for Aegerion's novel MTP inhibitor

Nov. 28, 2006

Novel agents with potential use in the treatment of obesity and lipoprotein disorders described

Nov. 27, 2006

Recent patents describe new agents for diabetes and other endocrine-related disorders

Nov. 27, 2006

Amura's orally active cathepsin K inhibitors show antiosteoclast activity

Nov. 27, 2006

Novel E-selectin antagonist may be useful to prevent vascular damage in diabetes

Nov. 27, 2006

Preclinical observations describe CRD-5's mechanism of action

Nov. 27, 2006

Phase III studies detail efficacy of CERA in chronic kidney disease patients

Nov. 27, 2006

MK-0524 improves niacin-induced flushing

Nov. 27, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...